The expression of the novel immune checkpoints, such as LAG3, TIM3, and TIGIT, was likewise higher in the high-risk group, suggesting that these molecules may play a key role in immunosuppression in high-risk AML patients. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.